Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis.
Ontology highlight
ABSTRACT: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome that is most commonly treated with etoposide and dexamethasone. This standard of care therapy has improved survival, but ∼15% of patients still die in the first months after diagnosis, and poor responses prompting salvage therapy are frequent. Thus, identifying patients at risk promptly is likely to improve outcomes. We conducted a multi-institutional, retrospective study of pediatric and young adults treated per HLH-94 or HLH-2004 from 2010 to 2019 to identify patients at risk for early mortality. Biweekly data during the first 100 days of treatment were analyzed using receiver operating curves to define optimal prognostic indicators and their thresholds. The primary end point was survival to bone ma
SUBMITTER: Verkamp B
PROVIDER: S-EPMC10698531 | biostudies-literature | 2023 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA